GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB.WS) » Definitions » Price-to-Funds-From-Operations

Nuvation Bio (Nuvation Bio) Price-to-Funds-From-Operations : (As of May. 01, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Nuvation Bio Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Nuvation Bio (Nuvation Bio) Business Description

Traded in Other Exchanges
Address
1500 Broadway, Suite 1401, New York, NY, USA, 10036
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).